OLD National Bancorp IN lowered its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 6.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,270 shares of the medical research company’s stock after selling 5,769 shares during the period. Thermo Fisher Scientific comprises about 0.9% of OLD National Bancorp IN’s holdings, making the stock its 26th largest holding. OLD National Bancorp IN’s holdings in Thermo Fisher Scientific were worth $16,323,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Proficio Capital Partners LLC lifted its stake in Thermo Fisher Scientific by 71.5% during the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares during the last quarter. Cribstone Capital Management LLC lifted its stake in Thermo Fisher Scientific by 8.7% during the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the second quarter worth about $113,000. Chicago Partners Investment Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter worth about $108,000. Finally, Ropes Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares during the last quarter. 86.16% of the stock is owned by hedge funds and other institutional investors.
In related news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.49% of the stock is owned by insiders.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded up $1.42 during trading hours on Wednesday, reaching $183.87. The company had a trading volume of 2,262,940 shares, compared to its average volume of 1,561,328. Thermo Fisher Scientific Inc has a 52 week low of $139.88 and a 52 week high of $201.20. The stock has a market cap of $72,570.00, a P/E ratio of 20.00, a PEG ratio of 1.67 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. During the same quarter in the previous year, the business earned $2.03 EPS. Thermo Fisher Scientific’s revenue was up 13.9% compared to the same quarter last year. equities research analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.19%.
Several research firms have recently commented on TMO. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen reiterated a “buy” rating and issued a $200.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Morgan Stanley reiterated an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a report on Thursday, September 7th. Finally, Barclays reiterated an “overweight” rating and issued a $215.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus price target of $205.21.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/12/07/thermo-fisher-scientific-inc-tmo-shares-sold-by-old-national-bancorp-in.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.